Free Trial

CalciMedica (CALC) Competitors

CalciMedica logo
$3.27 +0.01 (+0.18%)
As of 03:30 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CALC vs. SXTC, FTLF, TARA, IPHA, CRBP, GNLX, AVTX, FBRX, MIST, and MCRB

Should you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include China SXT Pharmaceuticals (SXTC), FitLife Brands (FTLF), Protara Therapeutics (TARA), Innate Pharma (IPHA), Corbus Pharmaceuticals (CRBP), Genelux (GNLX), Avalo Therapeutics (AVTX), Forte Biosciences (FBRX), Milestone Pharmaceuticals (MIST), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry.

CalciMedica vs. Its Competitors

CalciMedica (NASDAQ:CALC) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

In the previous week, CalciMedica and CalciMedica both had 3 articles in the media. CalciMedica's average media sentiment score of 0.95 beat China SXT Pharmaceuticals' score of 0.83 indicating that CalciMedica is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CalciMedica
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
China SXT Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CalciMedica has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.

CalciMedica currently has a consensus price target of $16.00, suggesting a potential upside of 389.90%. Given CalciMedica's stronger consensus rating and higher possible upside, equities analysts clearly believe CalciMedica is more favorable than China SXT Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CalciMedica
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

China SXT Pharmaceuticals' return on equity of 0.00% beat CalciMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
CalciMedicaN/A -206.51% -103.81%
China SXT Pharmaceuticals N/A N/A N/A

5.0% of China SXT Pharmaceuticals shares are held by institutional investors. 41.6% of CalciMedica shares are held by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

China SXT Pharmaceuticals has higher revenue and earnings than CalciMedica.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CalciMedicaN/AN/A-$13.70M-$1.60-2.04
China SXT Pharmaceuticals$1.74M95.69-$3.30MN/AN/A

Summary

China SXT Pharmaceuticals beats CalciMedica on 6 of the 11 factors compared between the two stocks.

Get CalciMedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALC vs. The Competition

MetricCalciMedicaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$45.63M$3.37B$6.05B$10.51B
Dividend YieldN/A2.31%5.73%4.82%
P/E Ratio-2.0422.2185.5327.36
Price / SalesN/A472.84592.56135.63
Price / CashN/A44.9825.7730.18
Price / Book3.0510.4612.696.79
Net Income-$13.70M-$52.58M$3.32B$276.59M
7 Day Performance-3.66%1.15%0.58%1.08%
1 Month Performance3.03%14.95%9.50%8.50%
1 Year Performance-18.15%21.65%79.27%44.54%

CalciMedica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CALC
CalciMedica
2.5389 of 5 stars
$3.27
+0.2%
$16.00
+389.9%
-14.4%$45.63MN/A-2.0430News Coverage
SXTC
China SXT Pharmaceuticals
0.3841 of 5 stars
$1.63
-0.4%
N/A-68.2%$189.59M$1.74M0.0090Gap Down
FTLF
FitLife Brands
3.8966 of 5 stars
$20.06
+1.6%
$23.00
+14.7%
+26.0%$188.38M$63.05M23.8820
TARA
Protara Therapeutics
2.1631 of 5 stars
$4.82
-1.0%
$19.60
+306.6%
+217.9%$185.97MN/A-2.9830
IPHA
Innate Pharma
3.1489 of 5 stars
$1.96
-0.8%
$6.50
+231.6%
-6.8%$180.68M$6.00M0.00220Gap Up
CRBP
Corbus Pharmaceuticals
3.8619 of 5 stars
$14.61
+0.6%
$45.43
+210.9%
-13.1%$179.05MN/A-3.0740
GNLX
Genelux
1.2604 of 5 stars
$4.71
+3.7%
$20.33
+331.7%
+101.1%$177.90M$10K-5.4810
AVTX
Avalo Therapeutics
3.2006 of 5 stars
$13.48
-3.7%
$31.67
+134.9%
+43.3%$177.26M$440K0.0040Analyst Forecast
FBRX
Forte Biosciences
2.6703 of 5 stars
$14.23
-1.4%
$68.00
+377.9%
+224.2%$176.92MN/A-0.875
MIST
Milestone Pharmaceuticals
2.0928 of 5 stars
$2.08
-1.9%
$4.50
+116.3%
+37.2%$176.79MN/A-2.4830
MCRB
Seres Therapeutics
2.1804 of 5 stars
$20.09
-4.3%
$14.33
-28.7%
+19.2%$175.79M$126.32M-4.37330News Coverage
Positive News

Related Companies and Tools


This page (NASDAQ:CALC) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners